The mystical experience is a potential psychological mechanism to influence outcome in
psychedelic therapy. It includes features such as oceanic boundlessness, ego dissolution …

Cognitive neuroscience studies in humans have enabled decades of impactful discoveries
but have primarily been limited to recording the brain activity of immobile participants in a …

Background COMP360 is a proprietary, synthetic formulation of psilocybin being developed
for treatment-resistant depression (TRD), a burdensome, life-threatening illness with high …

Background Psychedelic therapy shows promise for Major Depressive Disorder, especially
when treatment-resistant, as well as life-threatening illness distress. The objective of this …

Background Patients suffering from depression experience significant mood, anxiety, and
cognitive symptoms. Currently, most antidepressants work by altering neurotransmitter …

Major depressive disorder is a leading cause of disability worldwide. Because conventional
therapies are ineffective in many patients, novel strategies are needed to overcome …

Noninvasive brain stimulation/modulation is a rapidly emerging technique that has been
implemented in different clinical applications. The commonly noninvasive techniques used …

Depressive disorders can affect up to 350 million people worldwide, and in developed
countries, the percentage of patients with depressive disorders may be as high as 10 …

The growing interest in the rapid and sustained antidepressant effects of the dissociative
anesthetic ketamine and classic psychedelics, such as psilocybin, is remarkable. However …

Abstract Introduction The Major Depressive Disorder (MDD) is a mental health disorder that
affects millions of people worldwide. It is characterized by persistent feelings of sadness …